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Abstract
Background: It remains unsettled whether alcoholic cirrhosis is a risk factor for myocardial 
infarction (MI). 
Methods: We used data from nationwide healthcare registries to study all Danes diagnosed with 
alcoholic cirrhosis in 1996–2014, and five controls were matched to each of them on gender and 
age. We excluded everyone with ischemic heart disease and used Cox regression to estimate the 
incidence rate ratio of MI adjusted for potential cardiovascular confounders. Further, we 
described the MI-risk with non-MI death as a competing risk.
Results: We included 22,867 patients (67% men) with a median age of 57 years. During the first 
year of follow-up, their incidence rate ratio of MI was increased to 1.24 (95% CI: 0.94–1.62), 
driven by the effect among women (2.13, 95% CI: 1.17–3.87) and those with most severe 
cirrhosis (1.32, 95% CI: 0.91–1.90). After the first year, the overall incidence rate ratio fell to 
(0.89, 95% CI: 0.76–1.05). Patients were more likely to die from non-MI causes (33.7% vs. 1.0%), 
which protected them against MI. The overall 1-year MI-risk was similar in patients and controls: 
0.38% (95% CI: 0.30–0.47%) vs. 0.34% (95% CI: 0.31–0.38%). After five years of follow-up, male 
patients had lower MI-risk than their controls, whereas women with cirrhosis had an increased 
MI-risk throughout follow-up. 
Conclusions: The incidence rate of MI was increased the first year following a diagnosis of 
alcoholic cirrhosis, in particular in women and those with most severe liver disease. Due to the 
competing risk of non-MI mortality, the MI-risk was not increased.
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Introduction
Myocardial infarction (MI) is a leading cause of death worldwide.1 In patients with cirrhosis (80% 
alcoholic), cross-sectional evidence from computed tomography angiographies show a high 
prevalence of severe coronary stenosis.2-5 It appears that, statins reduce their mortality and rate 
of hepatic decompensation.6 Moreover, MI runs a particularly grave course in these patients and 
they have an increased mortality due to ischemic heart disease.7-9 On the other hand, their 
peripheral vasodilatation leads to a lower mean arterial pressure that might reduce cardiac 
strain and protect against acute coronary events.10 These seemingly contradictory observations 
raise two questions: First, is cirrhosis a cause of MI? We addressed this question by comparing 
the incidence rate of MI between alcoholic cirrhosis patients and matched controls. Second, do 
cirrhosis patients experience more MIs, taking their high risk of death from other causes into 
account?11 One reason for the unclear state of knowledge is that the two questions are in fact 
distinct and thus may have different answers. Neither has been answered before. We addressed 
them in an observational cohort study. We expected alcoholic cirrhosis patients to have a higher 
incidence rate of MI than controls, and that their actual risk of experiencing a MI is lower due to 
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Methods 
Data sources
We conducted a Danish nationwide population-based matched cohort study. All the 5.6 million 
Danish residents have free tax-funded access to hospital care.12 The Danish National Patient 
Registry (NPR) holds data on all admissions to Danish hospitals since 1977, and emergency room 
and outpatient visits since 1995. The data include relevant dates and discharge diagnoses coded 
in accordance with the International Classification of Disease edition 10 (ICD-10) from 1994, and 
the ICD-8 before that. Data also include surgical procedures coded in accordance with the 
Nordic Classification of Surgical Procedures (NCSP).13 
The Danish Civil Registration System continuously monitors the vital status including dates 
of death of all Danish residents.14 It also issues a unique personal identifier to all Danish residents 
at birth or immigration. This number enables unambiguous individual-level linkage between the 
NPR and the Danish Civil Registration System.14
Patients, population controls, and outcome
First, we identified all Danish residents with a first-time diagnosis of alcoholic cirrhosis (ICD-8: 
571.09; ICD-10: K70.3, K70.4) in 1996–2014. Second, we defined each patient’s ‘index date’ as 
the date of the first registration with the diagnosis alcoholic cirrhosis. Third, population controls 
from the general Danish population without alcoholic cirrhosis or unspecified cirrhosis (ICD-8: 
571.92, 571.99; ICD-10: K74.6) were matched to the alcoholic cirrhosis patients 5:1 on age, 
gender, and birthdate. The controls were given the same index date as their corresponding 
patient. Fourth, we excluded alcoholic cirrhosis patients (4.8%) and controls (3.9%) with a 
history of ischemic heart disease before their index date (ICD-10: I20.x, I21.x, I22.x, I23.x, I24.x, 
and I25.x), to focus on first-time MI. Fifth, patients were subcategorized as those with and 
without hepatic decompensation on or before the index date. Decompensation was defined as a 
diagnosis for ascites (ICD–10: R18.x), gastrointestinal hemorrhage (ICD-10: I85.9, K92.x), hepatic 
encephalopathy (ICD–10: K70.4, K72.x), portal hypertension (K76.6), hepatorenal syndrome 
(ICD–10: K76.7) or a procedure code for paracentesis (NCSP: KTJA10A and KTJA10B), before or 
on the index date. Finally, we defined the study outcome as the time to a hospital admission 
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Statistical analysis
Alcoholic cirrhosis patients and their controls were followed from the index date to the date of 
their first admission for MI, death, or end of follow-up on 31 December 2014, whichever 
occurred first. We compared the incidence rate of MI in alcoholic cirrhosis patients vs. controls 
with stratified Cox regression, and estimated the hazard ratio which reflects the incidence rate 
ratio for MI.15 We also adjusted for potential confounding by cardiovascular comorbidities 
registered in the NPR before the index date: diabetes, hypercholesterolemia, heart failure, 
peripheral vascular disease, atrial fibrillation or flutter, venous thromboembolism, hypertension, 
and obesity, and chronic obstructive pulmonary disease as a proxy indicator for smoking 
(diagnosis codes are listed in Table 1). We assessed whether the incidence rate ratio for MI 
changed over time using a plot of smoothed Schoenfeld residuals.16 This plot showed that there 
were two time-periods with distinct estimates. We also estimated incidence rate ratios in 
subgroups defined by gender, age on the index date (≤49, 50–64, or ≥65 years), and 
compensated or decompensated cirrhosis. 
An increased incidence rate (events divided by total follow-up time) does not necessarily 
predict an increased risk (the proportion of person alive at the beginning of follow-up that 
experience an event), since the risk also depends on the rate of competing risks, in this case 
death of other causes than MI (‘non-MI deaths’).11 Therefore, the risk for myocardial becomes 
lower when non-MI mortality rises. To illustrate the contrast in non-MI mortality between 
alcoholic cirrhosis patients and controls, we computed their non-MI mortality rates. Finally, we 
used the cumulated incidence function with non-MI death as a competing risk to compute the 
risk for MI.11 
Results
We included 22,867 patients with alcoholic cirrhosis and 107,485 matched controls; their 
median age was 57 years and 67% were males. The patients, in particular the males, had a 
higher prevalence of all cardiovascular comorbidities and of chronic obstructive pulmonary 
disease (Table 1). We followed the patients for a total of 79,423 years and observed 281 MIs, 
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were followed for 892,310 years and experienced 3,267 MIs, corresponding to a crude incidence 
rate of 3.7 (95% CI: 3.5–3.8) per 1,000 person years. After adjustment for the higher prevalence 
of confounders among patients with alcoholic cirrhosis, the overall incidence rates were virtually 
identical: 0.98 (95% 0.86–1.13). However, the time plots revealed that the incidence rate for the 
patients with alcoholic cirrhosis was not constant: They had a higher incidence during their first 
year after cirrhosis diagnosis, but a lower incidence rate thereafter (Table 2 and Figure 1). We 
therefore divided the follow-up period into the first year with an adjusted incidence rate ratio of 
1.24 (95% CI: 0.94–1.62) and the remaining follow-up with an adjusted incidence rate ratio of 
0.89 (95% CI: 0.76–1.05) (Table 2 and Figure 1). The increased incidence rate of MI in the first 
year was driven by a markedly increased adjusted incidence rate ratio for the patients with 
decompensated cirrhosis of 1.32 (95% CI: 0.91–1.90) and a marked increase in women of 2.13 
(95% CI: 1.17–3.87) (Table 2). 
The patients with alcoholic cirrhosis had a markedly higher mortality rate from non-MI 
causes: 203.7 (95% CI: 200.6–206.9) per 1,000 person years vs. 14.1 (95% CI: 13.8–14.3) per 
1,000 person years in the controls. This fact reduced their prospects of being alive and at risk for 
experiencing a MI. Thus, their 1-year risk of MI was essentially the same as that of the controls: 
0.38% (95% CI: 0.30–0.47%) vs. 0.34% (95% CI: 0.31–0.38%), and their 5-year risk of MI was 
actually lower: 1.01% (95% CI: 0.88–1.15) vs. 1.64% (95% CI: 1.55–1.72). This difference was 
most evident for the oldest age group where the 5-year risk of MI was 1.51% (95 % CI: 1.17–
1.91) for the patients with alcoholic cirrhosis compared with 3.33% (95% CI: 3.08–3.60) for their 
controls. The female patients had a higher incidence rate ratio for MI than males. At the same 
time, their non-MI mortality rate was lower than male patients’: 175 (95% CI: 170–180) vs. 221 
(95% CI: 217–225) per 1,000 person years. These differences explain why the 1-year risk of MI 
was higher for women with alcoholic cirrhosis than for controls: 0.33% (95% CI: 0.22–0.49) vs. 
0.16 (95% CI: 0.13–0.21). They also explain why women with alcoholic cirrhosis remained at 
increased risk of MI throughout the follow-up (Table 2 and Figure 2).
Discussion
We demonstrated how the incidence rate and the risk of MI in patients with alcoholic cirrhosis 
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this issue,2, 17 both regarding causality and clinical risk. The patients had an increased incidence 
rate of MI during the first year after they were diagnosed with alcoholic cirrhosis, most evident 
in women and in those with decompensated cirrhosis. Concerning the MI risk, the patients’ high 
mortality from other causes resulted in an only slightly elevated first-year risk, and a lower 5-
year risk. For the women with cirrhosis, the risk for MI remained elevated throughout follow-up. 
This detailed temporal description was possible because our study’s foundation in the 
Danish nationwide healthcare databases that enable a population-based design, precise 
estimates, and complete long-term follow-up.18, 19 The registry’s positive predictive value is 95% 
for alcoholic cirrhosis and above 90% for MI.20, 21 Thus, misclassification is likely negligible. We 
controlled for confounding from demographic characteristics and the prevalence of 
cardiovascular risk factors. Even though these factors were most prevalent in men, we found the 
highest incidence rate ratio of MI for women with alcoholic cirrhosis compared with their 
controls. Moreover, the adjustment for these confounders in women only altered the estimate 
of their incidence rate ratio of MI by less than 10% (from 2.36 to 2.13). 
A limitation was that data on antidiabetic, lipid-lowering, antihypertensive, and 
antiarrhythmic drug use were unavailable, but we do not find it plausible that our findings can 
be explained by a more widespread use of preventive medications in the controls. Importantly, 
confounding is a concern only relating to the incidence rate ratios, whereas the clinical risk 
estimates are unaffected by confounding, but highly influenced by death from competing risks.
We could not distinguish the effect of cirrhosis from that of alcohol itself, as a cohort of 
patients with non-alcoholic cirrhosis, or a cohort of patients with harmful alcohol intake without 
cirrhosis was unavailable. Moreover, etiologies other than alcohol are not well registered in the 
NPR.22 Therefore, we cannot tell whether non-alcoholic cirrhosis or alcoholism is associated with 
MI in the same temporal way. Concerning other etiologies, cumulated evidence suggests that 
chronic hepatitis C is associated with MI23 , in support of a relationship between liver disease 
and MI.
Cirrhotic cardiomyopathy is believed to be the major cardiac dysfunction in cirrhosis 
patients.24 However, cirrhosis patients also have markedly worse coronary atherosclerosis than 
healthy individuals 3, and are at an increased risk for venous thromboembolism.25 In addition, 
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Such events are accompanied by systemic inflammation activation, increased sympathetic 
nervous tone, and increased cardiac output.10, 27, 28 These mechanisms may exert an 
extraordinary energy and oxygen demand on the myocardium and explain the increased 
incidence rate of MI we found immediately after the cirrhosis diagnosis. Moreover, drugs for 
hepatic decompensation introduced later in follow-up (e.g. non-selective beta-blockers and 
diuretics) may contribute towards the lower MI incidence rate later in follow-up. Serial data on 
these factors along with data on hemodynamics, metabolic vs. excretory hepatic dysfunction, or 
on the hepatic venous pressure gradient might have helped us mechanistically explore our 
findings, but such information was unavailable to us.  
As opposed to men, women with alcoholic cirrhosis had more than two times higher 
incidence rate of MI compared with controls during their first year of follow-up. Adjustment for 
confounders only lowered this ratio slightly, and this pattern supports that alcoholic cirrhosis is a 
cause of myocardial infarction in women alone; though the association might also be due to 
residual or unmeasured confounding. Nevertheless, it remains possible that alcoholic cirrhosis 
somehow reduces the widely discussed, but unexplained gender gap in incident MI found in the 
general population.29 Of note, men with alcoholic cirrhosis have an elevated estrogen level, that 
increase their risk for breast cancer.30 This hormonal disturbance might alter male cirrhosis 
patients’ circulation towards a ‘female’ and less harmful cardiovascular risk profile.
Among patients with MI those with alcoholic cirrhosis have a higher mortality than other 
patients with MI,9 but it is unclear whether that association is due to cardiac or hepatic causes. 
Therefore, our data motivate clinical research involving work-up for cardiovascular risk factors in 
newly diagnosed alcoholic cirrhosis patients. In addition, the clinical benefit of statins on 
cardiovascular outcomes among these patients could be pursued further.6 
In conclusion, we found an increased incidence rate of MI only during the first year after a 
diagnosis for alcoholic cirrhosis compared with controls, in particular in those with the most 
severe cirrhosis and in women. These findings support alcoholic cirrhosis as a risk factor for MI. 
However, the patients’ actual risk for experiencing a MI was reduced because of their multifold 
increased risk of competing non-MI deaths. The time dependence and the difference between 
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Table 1: Demographics and prevalence of potential confounders for patients with alcoholic cirrhosis and 
controls






Median age in years (25th–75th quartiles) -  57 (50–64) 57 (50–64)
Males (%) - 15,579 (68) 72,123 (67)
Age ≤ 49 years (%) - 5,676 (25) 27,601 (26)
Age 50–64 years (%) - 12,109 (53) 57,283 (53)
Age ≥ 65 years (%) - 5,082 (22) 22,601 (21)
Diabetes (%) E10.x, E11.x 3,623 (11.5) 3,474 (3.2)
Hypercholesterolemia (%) E78.x 695 (3.0) 2,216 (2.0)
Heart failure (%) I50.x, I11.0, I13.0 , I13.2 907 (4.0) 904 (0.8)
Peripheral vascular disease (%) I70.x–I74.x, I77.x 920 (4.0) 1,940 (1.8)
Atrial fibrillation (%) I48.x 1,013 (4.4) 2,190 (2.0)
Venous thromboembolism (%) I26.x, I80.1–I80.3 889 (3.9) 1,175 (1.1)
Arterial hypertension (%) I10.x–I15.x 2,852 (12.5) 7,045 (6.6)
Obesity (%) E65.x–E68.x 720 (3.2) 1,839 (1.7)
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Table 2: Incidence rates, cumulative incidence proportions (risks), adjusted incidence rate ratios for myocardial infarction among patients with alcoholic cirrhosis patients vs. 
controls, according to time since diagnosis and gender, age, and disease severity
Incidence rate (95% CI) per 1,000 person years Risks in % (95% CI) Adjusted incidence rate ratio (95% CI)








Controls Alcoholic cirrhosis Controls 
Total 5.1 (4.1–6.3) 3.4 (3.1–3.8) 3.1 (2.7–3.6) 3.7 (3.6–3.8) 0.38 (0.30–0.47) 0.34 (0.31–0.38) 1.01 (0.88–1.15) 1.64 (1.55–1.72) 1.24 (0.94–1.62) 0.89 (0.76–1.05)
Men 5.4 (4.2–7.0) 4.3 (3.8–4.8) 3.7 (3.1–4.4) 4.6 (4.4–4.7) 0.43 (0.38–0.48) 0.43 (0.38–0.48) 1.08 (0.92–1.27) 2.04 (1.93–2.16) 1.08 (0.79–1.47) 0.85 (0.71–1.02)
Women 4.4 (2.8–6.6) 1.7 (1.3–2.1) 2.1 (1.6–2.8) 2.0 (1.8–2.2) 0.33 (0.22–0.49) 0.16 (0.13–0.21) 0.85 (0.65–1.10) 0.80 (0.71–0.91) 2.13 (1.17–3.87) 1.08 (0.77–1.52)
Age ≤ 49 years 1.6 (0.6–3.2) 0.9 (0.6–1.3) 2.3 (1.7–3.0) 1.6 (1.4–1.8) 0.13 (0.06–0.25) 0.09 (0.06–0.13) 0.70 (0.50–0.97) 0.58 (0.49–0.68) 1.29 (0.40–4.14) 1.48 (1.05–2.09)
Age 50–64 years 4.8 (3.4–6.5) 3.1 (2.7–3.6) 3.2 (2.6–3.9) 3.8 (3.6–4.0) 0.36 (0.27–0.48) 0.32 (0.27–0.36) 0.96 (0.79–1.16) 1.54 (1.44–1.65) 1.29 (0.89–1.91) 0.85 (0.69–1.06)
Age ≥ 65 years 11 (7.7–15) 7.3 (6.2–8.5) 5.0 (3.6–6.8) 7.7 (7.2–8.2) 0.70 (0.50–0.96) 0.72 (0.61–0.84) 1.51 (1.17–1.91) 3.33 (3.08–3.60) 1.21 (0.79–1.84) 0.66 (0.47–0.93)
Compensated 5.0 (3.4–6.7) 3.4 (2.9–4.0) 2.9 (2.3–3.5) 3.9 (3.7–4.1) 0.39 (0.28–0.52) 0.38 (0.29–0.40) 1.03 (0.84–1.25) 1.77 (1.65–1.90) 1.07 (0.71–1.62) 0.80 (0.64–1.00)
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Figure 1. Adjusted incidence rate ratio (IRR) for myocardial infarction for patients with alcoholic cirrhosis vs. 
controls according to time since diagnosis for alcoholic cirrhosis, overall (left), men (middle) and women 
(right). Dashed lines and text in grey represents the IRR for myocardial infarction during the first year after 












Figure 2: Cumulative risk of myocardial infarction for patients with alcoholic cirrhosis and controls overall 
(left), men (middle), and women (right). 
